• Aboud-Pirak, E., Hurwitz, E., Pirak, M., & al. (1988). Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst , 80, 1605-1611. • Adam, R. (2007. Colorectal cancer with sincronous liver metastases. British Journal of Surgery , 94, 129-131. • Adam, R., Pascal, G., Azoulay, D., Tanaka, K., Castaing, D., & Bismuth, H. (2003). Liver resection for colorectal metastases: the third hepatectomy. Ann Surg , 238, 871-883.• Adnane, J., & al., e. (1991). BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene , 6, 659-663. • Agus, D. B., & al., e. (2002). Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell , 2, 127-137.• Albanell, J. e. (2002). Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. ,20,[110][111][112][113][114][115][116][117][118][119][120][121][122][123][124] • Albanell, J., Codony-Servat, J., Rojo, F., & al, e. (2001). Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.Cancer Res , 61, 6500-6510. • Alberts, B., Johnson, A., Lewis, J., Raff, M., Keith, R., & Walter, P. (2004).Biologia molecolare e della cellula (4 ed.). Zanichelli.• Allen, T. M. (2002). Ligand-targeted therapeutics in anticancer therapy. Nature Rev. Cancer , 2, 750-763.• Amado, R., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D., et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clinical Oncology , 26 (10), 1626-1634.• Anderson, S., Johnson, D., Harris, M., Engler, H., Hancock, W., Huang, W., et al. (1998). p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin Cancer Res , 5, 1649Res , 5, -1659 • Andre', T., Tabernero, J., van Cutsem, E., & al. (2007). Phase II study with Cetuximab plus FOLFOX-4 in first-line setting for epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC): final results.Am Soc Clin Oncol GI Symp , (Abstr 344).• Brabender, J., Danenberg, K., Metzger, R., & al. (2001). Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res , 7, 1850-1855. • Bromberg, J., Wrzeszczynska, M., Devgan, G., & al, e. (1999. Stat3 as an oncogene. Cell , 98, 295-303. • Bross, P. F. (2001). Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. , 7, 1490-1496. • Bruns, C., Harbison, M., Davis, D., & al. (2000. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res , 6, 1936-1948. • Bruns, C., Solorzano, C., Harbison, M., & al. (2000. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.Cancer Res , 60, 2926-2935. • Bumpers, H., Alosco, T., Wang, H., Petrelli, N., Hoover, E., & Bankert, R. (1996. Consistent hepatic metastases of human colorectal cancer in severe combined immunodeficient mice. J Surg Res , 61, 282-8.• Busse, D., Doughty, R., Ramsey, T., & al, e. (2000). Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem , 275, 6987-6995.• Capdevila, J., Elez, E., Macarulla, T., Ramos, F., & Ruiz-Echarri, M. (2009).Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Reviews , 35, 354-363. • Cappuzzo, F., & al, e. (2005). Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst , 97, 643-655. • Cappuzzo, F., Finocchiaro, G., Rossi, E., Janne, P., Carnaghi, C., Calandri, C., et al. (2008). EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Annals of Oncology , 19, 717-723. • Cappuzzo, F., Ligorio, C., Janne, P., Toschi, L., Rossi, E., Trisolini, R., et al. (2007). Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial. J Clin Oncol , 25 (16), 2248-2255. • Fan, Q. e. (2003. Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res , 63, 8930-8938.